Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways

Pain

Volumn 156, Issue 2, 2015, Pages 305-317

  Lopez Canul, Martha ^a,b   Palazzo, Enza ^c   Dominguez Lopez, Sergio ^a   Luongo, Livio ^c   Lacoste, Baptiste ^a   Comai, Stefano ^a   Angeloni, Debora ^d   Fraschini, Franco ^e   Boccella, Serena ^c   Spadoni, Gilberto ^f   Bedini, Annalida ^f   Tarzia, Giorgio ^f   Maione, Sabatino ^c   Granados Soto, Vinicio ^g   Gobbi, Gabriella ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSIDAD VERACRUZANA   (Mexico)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d SCUOLA SUPERIORE SANT ANNA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF URBINO   (Italy)

^g Department of Pharmacobiology   (Mexico)

Author keywords

MT2 receptors,UCM924; Neuropathic pain; Periaqueductal gray,ON OFF cells,Rostral ventromedial medulla,Melatonin

Indexed keywords

GABAPENTIN; HORMONE RECEPTOR BLOCKING AGENT; MELATONIN 2 RECEPTOR; PARTIAL AGONIST; ACETAMIDE DERIVATIVE; ANILINE DERIVATIVE; LIGAND; N-(2-((3-BROMOPHENYL)-(4-FLUOROPHENYL)AMINO)ETHYL)ACETAMIDE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN STEM; CONTROLLED STUDY; GLUTAMATERGIC SYNAPSE; HEART ELECTROPHYSIOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MICROINJECTION; MODEL; MOTOR COORDINATION; NEUROPATHIC PAIN; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; ROSTRAL VENTROMEDIAL MEDULLA; ROTAROD TEST; SPINAL NERVE LIGATION INJURY; TAIL FLICK TEST; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; NEURALGIA; PAIN MEASUREMENT; PROCEDURES; PYRAMIDAL TRACT; WISTAR RAT;

ACETAMIDES; ANILINE COMPOUNDS; ANIMALS; BRAIN STEM; LIGANDS; MALE; NEURALGIA; PAIN MEASUREMENT; PYRAMIDAL TRACTS; RATS; RATS, WISTAR; RECEPTOR, MELATONIN, MT2;

EID: 84926459907     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/01.j.pain.0000460311.71572.5f     Document Type: Article

References (72)

1. Ambriz-Tututi M, Granados-Soto V. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. PAIN 2007;132:273-80.
2. Ambriz-Tututi M, Rocha-Gonzalez HI, Cruz SL, Granados-Soto V. Melatonin: a hormone that modulates pain. Life Sci 2009;84:489-98.
3. Angeloni D, Longhi R, Fraschini E. Production and characterization of antibodies directed against the human melatonin receptors Mel-1a (mt1) and Mel-1b (MT2). Eur J Histochem 2000;44:199-204.
4. Arreola-Espino R, Urquiza-Marin H, Ambriz-Tututi M, Araiza-Saldana CI, Caram-Salas NL, Rocha-Gonzalez HI, Mixcoatl-Zecuatl T, Granados-Soto V. Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur J Pharmacol 2007;577:203-10.
5. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9: 807-19.
6. Brunner P, Sozer-Topcular N, Jockers R, Ravid R, Angeloni D, Fraschini F, Eckert A, Muller-Spahn F, Savaskan E. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur J Histochem 2006;50:311-6.
7. Burgess SE, Gardell LR, Ossipov MH, Malan TP Jr, Vanderah TW, Lai J, Porreca F. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J Neurosci 2002;22:5129-36.
8. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63.
9. Chiang RP, Huang CT, Tsai YJ. Melatonin reduces median nerve injury-induced mechanical hypersensitivity via inhibition of microglial p38 mitogen-activated protein kinase activation in rat cuneate nucleus. J Pineal Res 2013;54:232-44.
10. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 2014;39:6-21.
11. De Felice M, Sanoja R, Wang R, Vera-Portocarrero L, Oyarzo J, King T, Ossipov MH, Vanderah TW, Lai J, Dussor GO, Fields HL, Price TJ, Porreca F. Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. PAIN 2011;152:2701-9.
12. de Novellis V, Mariani L, Palazzo E, Vita D, Marabese I, Scafuro M, Rossi F, Maione S. Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. Neuroscience 2005;134:269-81.
13. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. PAIN 2000;87:149-58.
14. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980;20:441-62.
15. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005;27:101-10.
16. Dubocovich ML, Masana MI, Iacob S, Sauri DM. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol 1997;355:365-75.
17. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006;60:97-108.
18. El-Shenawy SM, Abdel-Salam OM, Baiuomy AR, El-Batran S, Arbid MS. Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. Pharmacol Res 2002;46:235-43.
19. Esposito E, Paterniti I, Mazzon E, Bramanti P, Cuzzocrea S. Melatonin reduces hyperalgesia associated with inflammation. J Pineal Res 2010; 49:321-31.
20. Esser MJ, Sawynok J. Acute amitriptyline in a rat model of neuropathic pain: differential symptom and route effects. PAIN 1999;80:643-53.
21. Fields H. State-dependent opioid control of pain. Nat Rev Neurosci 2004; 5:565-75.
22. Fields HL, Bry J, Hentall I, Zorman G. The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat. J Neurosci 1983; 3:2545-52.
23. Fields HL, Malick A, Burstein R. Dorsal horn projection targets of ON and OFF cells in the rostral ventromedial medulla. J Neurophysiol 1995;74: 1742-59.
24. Heinricher MM, Ingram SL. 5.41-The Brainstem and Nociceptive Modulation. In: Masland RH, Albright TD, Dallos P, Oertel D, Firestein S, Beauchamp GK, Bushnell MC, Basbaum AI, Kaas JH, Gardner EP, editors. The Senses: A Comprehensive Reference. New York: Academic Press, 2008. pp. 593-626.
25. Heinricher MM, Morgan MM, Tortorici V, Fields HL. Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience 1994;63:279-88.
26. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol 2004; 92:1982-9.
27. Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res Rev 2009; 60:214-25.
28. Heinricher MM, Tortorici V. Interference with GABA transmission in the rostral ventromedial medulla: disinhibition of off-cells as a central mechanism in nociceptive modulation. Neuroscience 1994;63:533-46.
29. Hernandez-Pacheco A, Araiza-Saldana CI, Granados-Soto V, Mixcoatl-Zecuatl T. Possible participation of the nitric oxide-cyclic GMP-protein kinase G-K1 channels pathway in the peripheral antinociception of melatonin. Eur J Pharmacol 2008;596:70-6.
30. Hussain SA, Al-Khalifa II, Jasim NA, Gorial FI. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011;50:267-71.
31. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. PAIN 1992;50: 355-63.
32. Kumar A, Meena S, Kalonia H, Gupta A, Kumar P. Effect of nitric oxide in protective effect of melatonin against chronic constriction sciatic nerve injury induced neuropathic pain in rats. Indian J Exp Biol 2011;49:664-71.
33. Liu YY, Yin D, Chen L, Qu WM, Chen CR, Laudon M, Cheng NN, Urade Y, Huang ZL. Piromelatine exerts antinociceptive effect via melatonin, opioid, and 5HT receptors and hypnotic effect via melatonin receptors in a mouse model of neuropathic pain. Psychopharmacology (Berl) 2014; 231:3973-85.
34. Lovick TA. Pro-nociceptive action of cholecystokinin in the periaqueductal grey: a role in neuropathic and anxiety-induced hyperalgesic states. Neurosci Biobehav Rev 2008;32:852-62.
35. Lu WZ, Song GH, Gwee KA, Ho KY. The effects of melatonin on colonic transit time in normal controls and IBS patients. Dig Dis Sci 2009;54: 1087-93.
36. Menendez-Pelaez A, Howes KA, Gonzalez-Brito A, Reiter RJ. N-acetyltransferase activity, hydroxyindole-O-methyltransferase activity, and melatonin levels in the Harderian glands of the female Syrian hamster: changes during the light:dark cycle and the effect of 6-parachlorophenylalanine administration. Biochem Biophys Res Commun 1987;145:1231-8.
37. Morimoto R, Hayashi M, Yatsushiro S, Otsuka M, Yamamoto A, Moriyama Y. Co-expression of vesicular glutamate transporters (VGLUT1 and VGLUT2) and their association with synaptic-like microvesicles in rat pinealocytes. J Neurochem 2003;84:382-91.
38. Musshoff U, Riewenherm D, Berger E, Fauteck JD, Speckmann EJ. Melatonin receptors in rat hippocampus: molecular and functional investigations. Hippocampus 2002;12:165-73.
39. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS. Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010;58:585-92.
40. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112.
41. Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G, Rivara S, Bedini A, Angeloni D, Fraschini F, Mor M, Tarzia G, Descarries L, Gobbi G. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 2011;31:18439-52.
42. Ochoa-Sanchez R, Comai S, Spadoni G, Bedini A, Tarzia G, Gobbi G. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states. Neurosci Lett 2014;561: 156-61.
43. Ochoa-Sanchez R, Rainer Q, Comai S, Spadoni G, Bedini A, Rivara S, Fraschini F, Mor M, Tarzia G, Gobbi G. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: Comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry 2012;39: 318-25.
44. Odo M, Koh K, Takada T, Yamashita A, Narita M, Kuzumaki N, Ikegami D, Sakai H, Iseki M, Inada E. Changes in circadian rhythm for mRNA expression of melatonin 1A and 1B receptors in the hypothalamus under a neuropathic pain-like state. Synapse 2014;68:153-8.
45. Ossipov MH, Lai J, King T, Vanderah TW, Malan TP Jr, Hruby VJ, Porreca F. Antinociceptive and nociceptive actions of opioids. J Neurobiol 2004;61: 126-48.
46. Palazzo E, Luongo L, de Novellis V, Rossi F, Marabese I, Maione S. Transient receptor potential vanilloid type 1 and pain development. Curr Opin Pharmacol 2012;12:9-17.
47. Pang CS, Tsang SF, Yang JC. Effectsofmelatonin, morphine and diazepam on formalin-induced nociception in mice. Life Sci 2001;68:943-51.
48. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press; 1986:55-60.
49. Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63:757.
50. Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP Jr, Ossipov MH, Lappi DA, Lai J. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J Neurosci 2001;21:5281-8.
51. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci 2002;25:319-25.
52. Raghavendra V, Agrewala JN, Kulkarni SK. Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol 2000;395:15-21.
53. Ray M, Mediratta PK, Mahajan P, Sharma KK. Evaluation of the role of melatonin in formalin-induced pain response in mice. Indian J Med Sci 2004;58:122-30.
54. Reyes-Garcia G, Caram-Salas NL, Medina-Santillan R, Granados-Soto V. Oral administration of B vitamins increases the antiallodynic effect of gabapentin in the rat. Proc West Pharmacol Soc 2004;47:76-9.
55. Rivara S, Vacondio F, Fioni A, Silva C, Carmi C, Mor M, Lucini V, Pannacci M, Caronno A, Scaglione F, Gobbi G, Spadoni G, Bedini A, Orlando P, Lucarini S, Tarzia G. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective and synthesis of melatonin receptor ligands. Chem Med Chem 2009;4:1746-55.
56. Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007;41: 29-32.
57. Sallinen P, Saarela S, Ilves M, Vakkuri O, Leppaluoto J. The expression of MT1 and MT2 melatonin receptor mRNA in several rat tissues. Life Sci 2005;76:1123-34.
58. Shin D, Jeong C, Lee S, Yoon M. Receptors involved in the antinociception of intrathecal melatonin in formalin test of rats. Neurosci Lett 2011;494:207-10.
59. Silva M, Amorim D, Almeida A, Tavares I, Pinto-Ribeiro F, Morgado C. Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain modulatory cells in the streptozotocin-diabetic rat. Brain Res Bull 2013;96:39-44.
60. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005;54:1402-7.
61. Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F, de Novellis V, Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 2007;27: 13739-49.
62. Tan DX, Manchester LC, Reiter RJ, Qi WB, Zhang M, Weintraub ST, Cabrera J, Sainz RM, Mayo JC. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999;1472:206-14.
63. Ulugol A, Dokmeci D, Guray G, Sapolyo N, Ozyigit F, Tamer M. Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: Possible involvements of the L-arginine-NO pathway and opioid system. Life Sci 2006;78:1592-7.
64. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 1998; 78:687-721.
65. Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Brain Res Rev 2004;46:295-309.
66. Wall PD, McMahon SB, Koltzenburg M. Wall and Melzack's Textbook of Pain. Elsevier Health Science Division, Philadelphia, PA, 2006.
67. Wang S, Zhang L, Lim G, Sung B, Tian Y, Chou CW, Hernstadt H, Rusanescu G, Ma Y, Mao J. A combined effect of dextromethorphan and melatonin on neuropathic pain behavior in rats. Brain Res 2009;1288:42-9.
68. Zahn PK, Lansmann T, Berger E, Speckmann EJ, Musshoff U. Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: implications for pain modulation. J Pineal Res 2003; 35:24-31.
69. Zeng Q, Wang S, Lim G, Yang L, Mao J, Sung B, Chang Y, Lim JA, Guo G. Exacerbated mechanical allodynia in rats with depression-like behavior. Brain Res 2008;1200:27-38.
70. Zhao C, Tall JM, Meyer RA, Raja SN. Antiallodynic effects of systemic and intrathecal morphine in the spared nerve injury model of neuropathic pain in rats. Anesthesiology 2004;100:905-11.
71. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. PAIN 1983;16:109-10.
72. Zurowski D, Nowak L, Machowska A, Wordliczek J, Thor PJ. Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism. J Physiol Pharmacol 2012;63: 641-7.